Development
GSK plc
GSK
$42.37
$0.74551.79%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -75.24% | -85.45% | 93.04% | -25.18% | 73.91% |
| Total Depreciation and Amortization | 557.57% | -34.87% | -50.90% | 38.54% | -140.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.42% | 99.09% | -28.07% | -87.59% | 25.06% |
| Change in Net Operating Assets | 260.32% | 3,863.70% | -1,102.31% | -1,015.46% | -164.37% |
| Cash from Operations | 77.44% | 80.08% | -20.37% | -98.11% | -55.94% |
| Capital Expenditure | -17.35% | -16.93% | -24.41% | -9.24% | -2.04% |
| Sale of Property, Plant, and Equipment | -94.43% | 69.00% | -- | 5.57% | 727.74% |
| Cash Acquisitions | 97.45% | 97.77% | -2,935.93% | 96.52% | -125.99% |
| Divestitures | 69.15% | 69.27% | 590.39% | -642.89% | -361.39% |
| Other Investing Activities | 724.65% | 81.14% | 366.83% | 95.32% | -584.90% |
| Cash from Investing | 152.49% | 87.10% | -76.19% | 89.73% | -30.33% |
| Total Debt Issued | -214.27% | -175.65% | -- | -- | 309.63% |
| Total Debt Repaid | 16.67% | 76.02% | 75.35% | 36.33% | 4.51% |
| Issuance of Common Stock | -- | -100.00% | -57.14% | -52.94% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | 71.43% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 8.15% | 13.51% | 52.00% | 47.25% | 40.08% |
| Other Financing Activities | 8.44% | -116.96% | 14.59% | -101.41% | 36.26% |
| Cash from Financing | -183.93% | -42.90% | 100.69% | -103.61% | 57.97% |
| Foreign Exchange rate Adjustments | -178.17% | 7.54% | -179.97% | -333.75% | 601.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -334.70% | 99.53% | 109.50% | -109.19% | -89.81% |